[{"address1": "15 Crosby Drive", "city": "Bedford", "state": "MA", "zip": "01730", "country": "United States", "phone": "781 357 4000", "fax": "781 275 7562", "website": "https://www.ocutx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.", "fullTimeEmployees": 267, "companyOfficers": [{"maxAge": 1, "name": "Mr. Donald  Notman Jr.", "title": "CFO, COO & Principal Accounting Officer", "fiscalYear": 2023, "totalPay": 679770, "exercisedValue": 0, "unexercisedValue": 90888}, {"maxAge": 1, "name": "Dr. Jeffrey S. Heier M.D.", "age": 63, "title": "Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 86162, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Pravin U. Dugel M.D.", "age": 60, "title": "Executive Chairman, President & CEO", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter K. Jarrett Ph.D.", "age": 67, "title": "Chief Technology Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William S. Slattery Jr.", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Todd D.C. Anderman J.D.", "title": "Chief Legal Officer & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. William H. Ransone II", "title": "Vice President of Global Sales & Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Barry  Rubenstein M.S.", "title": "Chief Human Resources Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Steve  Meyers", "title": "Chief Commercial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter K. Kaiser M.D.", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 7.25, "open": 7.35, "dayLow": 6.99, "dayHigh": 7.41, "regularMarketPreviousClose": 7.25, "regularMarketOpen": 7.35, "regularMarketDayLow": 6.99, "regularMarketDayHigh": 7.41, "payoutRatio": 0.0, "beta": 1.218, "forwardPE": -6.8627453, "volume": 638578, "regularMarketVolume": 638578, "averageVolume": 901374, "averageVolume10days": 954820, "averageDailyVolume10Day": 954820, "bid": 6.97, "ask": 7.02, "bidSize": 2, "askSize": 2, "marketCap": 1100518912, "fiftyTwoWeekLow": 4.06, "fiftyTwoWeekHigh": 11.775, "priceToSalesTrailing12Months": 17.911509, "fiftyDayAverage": 8.2227, "twoHundredDayAverage": 8.20505, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 787730368, "profitMargins": -2.8374398, "floatShares": 122385906, "sharesOutstanding": 157216992, "sharesShort": 10872561, "sharesShortPriorMonth": 10736923, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0692, "heldPercentInsiders": 0.01148, "heldPercentInstitutions": 0.86061996, "shortRatio": 11.85, "shortPercentOfFloat": 0.0694, "impliedSharesOutstanding": 157216992, "bookValue": 2.247, "priceToBook": 3.115265, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -174338000, "trailingEps": -1.29, "forwardEps": -1.02, "enterpriseToRevenue": 12.821, "enterpriseToEbitda": -5.665, "52WeekChange": -0.2647059, "SandP52WeekChange": 0.2021538, "quoteType": "EQUITY", "currentPrice": 7.0, "targetHighPrice": 22.0, "targetLowPrice": 14.0, "targetMeanPrice": 18.22222, "targetMedianPrice": 18.0, "recommendationMean": 1.44444, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 427220000, "totalCashPerShare": 2.717, "ebitda": -139063008, "totalDebt": 75124000, "quickRatio": 12.593, "currentRatio": 13.009, "totalRevenue": 61442000, "debtToEquity": 21.341, "revenuePerShare": 0.447, "returnOnAssets": -0.27356002, "returnOnEquity": -0.96888, "grossProfits": -47181000, "freeCashflow": -79564752, "operatingCashflow": -117702000, "revenueGrowth": 0.023, "grossMargins": -0.76789004, "ebitdaMargins": -2.26332, "operatingMargins": -2.9820402, "financialCurrency": "USD", "symbol": "OCUL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Ocular Therapeutix, Inc.", "shortName": "Ocular Therapeutix, Inc.", "corporateActions": [], "postMarketTime": 1740171718, "regularMarketTime": 1740171601, "exchange": "NGM", "messageBoardId": "finmb_41955650", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketPrice": 7.0, "regularMarketChangePercent": -3.4482758, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1406295000000, "postMarketChangePercent": 0.0, "postMarketPrice": 7.0, "postMarketChange": 0.0, "regularMarketChange": -0.25, "regularMarketDayRange": "6.99 - 7.41", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 901374, "fiftyTwoWeekLowChange": 2.94, "fiftyTwoWeekLowChangePercent": 0.72413796, "fiftyTwoWeekRange": "4.06 - 11.775", "fiftyTwoWeekHighChange": -4.7749996, "fiftyTwoWeekHighChangePercent": -0.40552014, "fiftyTwoWeekChangePercent": -26.470589, "marketState": "POST", "earningsTimestampStart": 1741604340, "earningsTimestampEnd": 1741953600, "earningsCallTimestampStart": 1731589200, "earningsCallTimestampEnd": 1731589200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.29, "epsForward": -1.02, "epsCurrentYear": -1.06667, "priceEpsCurrentYear": -6.56248, "fiftyDayAverageChange": -1.2227001, "fiftyDayAverageChangePercent": -0.14869812, "twoHundredDayAverageChange": -1.2050505, "twoHundredDayAverageChangePercent": -0.14686692, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "displayName": "Ocular Therapeutix", "trailingPegRatio": null, "__fetch_time": "2025-02-21"}]